Replies to post #6888 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>If…the need for lower cost drugs wasn't an issue then GTC would have a difficult time convincing investors that the company had a competitive advantage to exploit.<

In case anyone needs a reminder on the political impetus for lower-cost drugs, please see the big bad charts in #msg-23009572.